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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the analgesic efficacy and adverse events of TENS for fibromyalgia in adults. We will assess TENS on its own or added to
usual care in comparisons with placebo (sham) TENS, usual care, or no treatment.
B A C K G R O U N D
This protocol is based on a template for reviews of drugs used to
relieve fibromyalgia. The aim is for all reviews to use the same
methods, based on new criteria for what constitutes reliable evi-
dence in chronic pain (Moore 2010a; Appendix 1).
Description of the condition
Fibromyalgia is a long-termmedical condition that is characterised
by chronic widespread pain in the muscles and joints, with sen-
sitivity to pressure stimuli. The symptoms may vary from person
to person, but the main symptom is widespread pain through-
out the body. This may be worse in certain areas, such as the
back or neck. Pain may be described as aching, burning, stabbing,
or sharp and may be accompanied by hyperalgesia (heightened
sensitivity to pain) and allodynia (pain on very mild stimulus).
Pain is often continuous but it may fluctuate in severity depend-
ing on various factors including stress, physical activity, and the
weather. Exposure to certain environmental stimuli (e.g. smoke,
certain foods, and bright lights) may cause flare-ups. Other pre-
senting symptoms may include stiffness, especially in the morn-
ing; muscle spasm; depression; fatigue; poor sleep quality, includ-
ing non-restorative sleep; cognitive difficulties in thinking, learn-
ing, attention and concentration; headaches, including severe mi-
graines; and irritable bowel syndrome (Wolfe 2014). Originally,
the American College of Rheumatology diagnostic criteria for fi-
bromyalgia were widespread pain (axial pain, left- and right-sided
pain, upper and lower segment pain) that lasts for longer than
three months, with pain on palpation at 11 or more of 18 spec-
ified tender points (Wolfe 1990). More recently, a definition of
fibromyalgia has been proposed based on symptom severity and
the presence of widespread pain, which does not require palpation
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of tender points for diagnosis (Wolfe 2010). Thus, fibromyalgia is
diagnosed if the patient has: a widespread pain index (WPI) of >
7 and a symptom severity scale score of > 5, or a WPI of between
3 and 6 and a symptom severity scale score of > 9; symptoms have
persisted at a similar level for > 3 months; and the pain cannot be
explained by another disorder.
While some rheumatologists have thought of fibromyalgia as a
specific pain disorder, other investigators have characterised it as
a bodily distress syndrome or a physical symptom disorder, or so-
matoform disorder (Wolfe 2014). It is a heterogeneous condition
in which there is abnormal processing of the sensation of pain.
The cause, or causes, are not well understood, but it has features
in common with neuropathic pain, including changes in the cen-
tral nervous system (CNS). Moreover, people with neuropathic
pain and people with fibromyalgia experience similar sensory phe-
nomena (Koroschetz 2011). Many people with fibromyalgia are
significantly disabled, and experience moderate or severe pain for
many years. Chronic painful conditions comprised five of the 11
top-ranking conditions for years lived with disability in 2010 (Vos
2012), and are responsible for considerable loss of quality of life,
employment, and increased health costs (Moore 2014a).
Fibromyalgia is common. Numerous studies have investigated
prevalence in different settings and countries. The Queiroz 2013
review gives a global mean prevalence of 2.7% (range 0.4% to
9.3%), and a mean in the Americas of 3.1%, in Europe of 2.5%,
and in Asia of 1.7%. Fibromyalgia is more common in women,
with a female to male ratio of 3:1 (4.2%:1.4%). The change in
diagnostic criteria does not appear to have significantly affected
estimates of prevalence (Wolfe 2013). Estimates of prevalence in
specific populations vary greatly, but have been reported to be
as high as 9% in female textile workers in Turkey and 10% in
metalworkers in Brazil (59% in those with repetitive strain in-
jury; Queiroz 2013). Risk factors for fibromyalgia include: sex (it
is more common in women than in men); family history (it is
more likely if a relative has the condition); and rheumatic dis-
ease (rheumatoid arthritis or lupus). The financial burden of fi-
bromyalgia on society is significant. A cross-sectional study on
299 patients with fibromyalgia in France and Germany estimated
that, on average, patients visited their physician 11.6 (France) and
19.6 (Germany) times per year and missed 32.4 and 25.2 days
of work per year respectively (Winklemann 2011). Total annual
costs to society based on three-month data from 2008 were EUR
7900 in France and EUR 7256 in Germany per person. Direct
costs from physician office visits, medications, and out-of-pocket
expenses were EUR 910 (France) and EUR 1765 (Germany), and
indirect costs frommissed days of work and lost productivity were
EUR 6990 (France) and EUR5491 (Germany). Costs were found
to increase by more than 200% for mild and severe fibromyalgia.
There are no definitive treatments for fibromyalgia. Fibromyalgia
pain is difficult to treat effectively, with only a minority of indi-
viduals experiencing a clinically relevant benefit from any one in-
tervention. A multidisciplinary approach is now advocated, with
pharmacological interventions being combined with physical or
cognitive interventions, or both. Conventional analgesics are usu-
ally not effective. Treatment is often by so-called unconventional
analgesics, such as antidepressants like duloxetine and amitripty-
line (Lunn 2014; Moore 2012a; Sultan 2008), or antiepileptics
like gabapentin or pregabalin (Moore 2009;Moore 2011a;Wiffen
2013). The proportion of people who achieve worthwhile pain
relief (typically at least a 50% reduction in pain intensity; Moore
2013b) is small, generally only 10% to 25% more than with
placebo, with numbers needed to treat to benefit (NNTB) usually
between 4 and 10 (Wiffen 2013). Those who do experience good
levels of pain relief, however, also benefit from substantial reduc-
tions in other symptoms, such as fatigue, function, sleep, depres-
sion, anxiety, and ability to work, with significant improvement
in quality of life (Moore 2010b; Moore 2014a; Straube 2011).
Fibromyalgia is not particularly different from other chronic pain
in that only a small proportion of trial participants have a good
response to treatment (Moore 2013b).
Description of the intervention
Transcutaneous Electrical Nerve Stimulation (TENS) is the deliv-
ery of pulsed electrical currents across the intact surface of the skin
to stimulate peripheral nerves, principally for pain relief (APTA
2001; Johnson 2014). TENS treatment is usually self adminis-
tered by the patient, ideally following instruction from a health-
care practitioner. A portable, battery-poweredTENSdevice is used
to produce the electrical currents and these are delivered to the
body using self adhering electrodes attached to the surface of the
skin. TENS is inexpensive, with a good safety profile compared
with medication. TENS devices and accessories (lead wires and
self adhering electrodes) are available without prescription. Robust
safety guidelines have been published by professional bodies to
guide judgements about the appropriateness of TENS in certain
situations (Houghton 2010). Contraindications include patients
who also have cardiac pacemakers and implantable cardioverter de-
fibrillators. Precautions include pregnancy, epilepsy, active malig-
nancy, deep-vein thrombosis, and frail or damaged skin (Johnson
2011).
TENS devices create pulsed currents with asymmetrical biphasic
rectangular or symmetrical biphasic rectangularwaveforms.TENS
devices are designed so that users can adjust the electrical charac-
teristics of the currents including: pulse frequency (usually < 200
Hz), pulse amplitude (usually < 70 mA), pulse duration (usually
50 to 250 microseconds), and pulse pattern (sometimes termed
’mode’ and including continuous, burst, and modulated). Modu-
lated pulse patterns may help to reduce tolerance to TENS caused
by repeated use and include modulated frequency, modulated am-
plitude, and modulated duration (Sluka 2013).
Two TENS techniques have been defined by the International
Association for the Study of Pain and are commonly used in the
literature (Charlton 2005): conventional TENS administered us-
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ing high-frequency, low-intensity currents to produce a strong
non-painful TENS sensation; and acupuncture-like TENS (AL-
TENS) using low-frequency, high-intensity currents to produce
strong non-painful pulsate sensations, phasic muscle contractions
(twitching), or both (Claydon 2008a). Low-frequency TENS is
consistently defined as the delivery of pulsed current < 10 Hz
or low-frequency trains (bursts) of high-frequency pulsed current
(i.e. burst mode TENS). High-frequency TENS is often described
as pulsed current between ~50 Hz and 100 Hz, although this
neglects frequencies between 11 Hz and 49 Hz and frequencies
above 100 Hz. The term medium-frequency TENS is rarely used
in the literature so high-frequency TENS should be used to de-
scribe frequencies > 10 Hz to the maximum setting on the TENS
device, which is usually 150 Hz to 200 Hz (Johnson 2014). High-
frequency TENS is not always applied at a low intensity and low-
frequency TENS is not always applied at a high intensity. Low-
frequency TENS applied 10% below motor threshold has been
shown to generate analgesia in humans and reduce primary and
secondary joint inflammation in animal models of nociception
(Chen 2008; King 2001; Sluka 1998; Sluka 2013; Vance 2007).
The critical factor for response to TENS is the perceptual experi-
ence of the intensity of currents during stimulation regardless of
frequency. Evidence suggests that optimal hypoalgesia is achieved
using pulse amplitudes (mA) that generate a strong, non-painful
TENS sensation and therefore pulse amplitude should be titrated
during treatment to maintain this intensity level (Bjordal 2003;
Moran 2011; Sluka 2013). Thus, this review will include a sub-
group analysis of intensity (’strong’ versus ’barely perceptible’),
frequency (low-frequency versus high-frequency when intensity is
’strong’), and technique (conventional TENS versus AL-TENS).
Response to TENS is also influenced by site of stimulation ac-
cording to the placement of electrodes. Best practice guidelines
suggest that electrodes should be placed on healthy sensate skin so
that the TENS sensation covers (permeates) the painful area. This
is achieved by placing electrodes directly over or ’bracketing’ the
painful site. This may not always be possible because, for example,
skin sensation is altered, there is a skin lesion, or a body part is
absent. In these circumstances electrodes are placed over the main
nerves proximal to the site of pain, close to vertebrae of spinal
segments, over contralateral dermatomes, over acupuncture points
(acu-TENS), or over myofascial trigger points. Research findings
on the effect of the site of stimulation on treatment outcome are
ambiguous (Johnson 2014). Consideration also needs to be given
to the duration and regularity of treatment and the timing of out-
come measurements. In particular, evidence suggests that the ef-
fects of TENS are maximal during stimulation or immediately
after stimulation (Sluka 2013), and that some studies have failed
to measure outcome during stimulation (Bennett 2011; Bjordal
2003). Thus, this review will include a subgroup analysis: during
TENS versus after TENS.
How the intervention might work
The theoretical underpinning for pain relief by electrical stimula-
tion of the skinwas established through the publication of theGate
Control Theory of Pain by Melzack and Wall (Melzack 1965).
They proposed that neural activity in low-threshold cutaneous
afferents (e.g. A-beta axons) would inhibit onward transmission
of nociceptive (pain-related) information in the spinal cord and
brainstem. Normally, activity in low-threshold cutaneous afferents
is generated by low-intensity mechanical stimuli such as ’rubbing
the skin’. They suggested that electrical currents could be used to
stimulate the low-threshold cutaneous afferents to reduce pain.
The physiological intention of using conventional TENS is to gen-
erate a strong but non-painful TENS sensation as this is indicative
of selective activation of low-threshold cutaneous afferents (A-beta
axons). Evidence suggests that this inhibits onward transmission
of nociceptive information at the first synapse in the spinal cord or
brain stem (i.e. segmental modulation; Garrison 1996; Ma 2001).
The intention of using AL-TENS is to generate pulsate sensations
in the skin and underlying tissue or non-painful muscle twitching
(or both) as this produces neural activity in small diameter muscle
afferents leading to activation of descending pain inhibitory path-
ways (DeSantana 2009; Francis 2011; Kalra 2001; Milan 2002).
TENS may also reduce nociceptive input to the central nervous
system by blocking incoming afferent activity in peripheral neu-
rons, creating a ’busy-line’ effect (Nardone 1989).
Research on animals suggests that low-frequency TENS, when ad-
ministered just below motor threshold, mediates effects via nora-
drenaline, serotonin, and mu opioid systems and high-frequency
TENS, when administered just below motor threshold, medi-
ates effects via noradrenaline, GABA, and delta opioid systems
(Kalra 2001; Leonard 2010; Maeda 2007; Santos 2013; Sluka
1999; Sluka 2006; Somers 2009). Whether the frequency-medi-
ated effects of TENS translate into differential hypoalgesia in hu-
mans when the intensity of TENS is kept constant remains in
doubt (Chen 2008; Claydon 2008a). There is evidence that long-
term use of opioid medication may impact negatively on response
to low-frequency TENS but not on response to high-frequency
TENS (Sluka 2000). Leonard 2011 found that high-frequency
TENS reduced pain in 12 opioid-treated chronic pain patients
and 11 opioid-naïve chronic pain patients, whereas low-frequency
TENS only reduced pain in the non-opioid group. The lack of
pain relief during low-frequency TENS was attributed to the de-
velopment of µ-opioid receptor tolerance.
Sham credibility issues in trials of TENS
Bennett 2011 examined aspects of fidelity that may contribute to
a risk of bias in TENS studies. Factors that contributed to the
overestimation of TENS effects included inadequate method of
randomisation, small sample sizes, and issues associated with the
implementation of a sham (placebo) control such as allocation
concealment and how blinding was maintained. Various types of
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sham control have been used in TENS studies, including deacti-
vated TENS devices that are identical in appearance but deliver
no current and TENS devices that deliver stimulation at the start
of treatment and fade to zero current output over a brief period
of time (e.g. within 45 seconds) (Rakel 2010). There are threats
to the credibility of this approach because active stimulation elic-
its sensations and introduces a risk of bias to sham-controlled in-
terventions. Thus, it is not possible to truly blind the patient to
the sensory experience generated by different types of TENS or
the lack of sensation during sham (no current) TENS (or both).
However, the nature of the TENS intervention can be concealed
during pre-study briefing using a process that calibrates the par-
ticipant’s expectations of sensations from study interventions. Par-
ticipants can be briefed that some types of non-invasive electrical
stimulation techniques do not produce sensations during stimu-
lation (i.e. microcurrent therapy) and that they may or may not
experience sensations from the TENS device (Bennett 2011). The
sham (no current) device can look and behave similarly to the in-
tervention device (e.g. identical appearance of the device, flashing
lights, and functioning display panel) and participants can be in-
structed to use the device at a pre-determined setting on the dis-
play. Blinding can be monitored by asking participants whether
they believed that “...the device was functioning properly?” (Deyo
1990). Bennett 2011 also examined aspects of fidelity that may
contribute to underestimation of the effects of TENS and found
that the adequacy of the TENS intervention (i.e. the appropriate-
ness of the TENS technique) was the main area of concern. Other
factors contributing to underestimation of the effects of TENS
were: a lack of instruction on how best to administer TENS es-
pecially when self administering TENS; assessment of adherence;
inadequate reporting of the TENS regimen during use; and failure
to standardise or report concurrent analgesia and to assess com-
parability between groups. We will undertake a subgroup analysis
of TENS administered as a sole treatment versus TENS adminis-
tered in combination with other treatments in this review.
Why it is important to do this review
TENS is used extensively to manage painful conditions because
it has few contra-indications or reported side effects and has
no potential for overdose (Johnson 2014). A Cochrane review
by Johnson 2015a concluded that there was tentative evidence
that TENS reduces pain intensity when administered as a stand-
alone treatment for acute pain in adults and a non-Cochrane
meta-analyses found superiority of TENS over placebo for reduc-
ing postoperative analgesic consumption (Bjordal 2003). Another
Cochrane review found only limited evidence of effect for labour
pain (Dowswell 2009). In 2008, a Cochrane review on TENS
for chronic pain was inconclusive (Nnoaham 2008); although the
2008 review has now been withdrawn, our new review will partly
serve to update it, focusing on fibromyalgia alone. Most Cochrane
reviews on specific chronic pain conditions have found the evi-
dence to be inconclusive (e.g. osteoarthritis of the knee (Rutjes
2009)) or insufficient to make a judgement (e.g. chronic low back
pain (Khadilkar 2008), cancer pain (Hurlow 2012), and phan-
tom pain and stump pain (Johnson 2015b)).NonCochranemeta-
analyses have found superiority of TENS over placebo for chronic
musculoskeletal pain (Johnson 2007), and osteoarthritis of the
knee (Bjordal 2007). Often systematic reviews and meta-analyses
are hindered bymethodological weaknesses including sub-optimal
TENS interventions and inadequate study sample sizes (Bennett
2011: Johnson 2010; Sluka 2013). An overview of Cochrane re-
views of TENS for chronic pain is in development (Catley 2015),
and a new review on TENS for neuropathic pain in adults, which
was developed from Claydon 2010, has been published (Gibson
2015).
There is evidence that electrode placement site, frequency and
intensity of stimulation influence TENS outcome although the
precise nature of the interaction is unknown (Chesterton 2003;
Claydon 2008b; Claydon 2013). Studies on healthy human par-
ticipants exposed to experimental pain and systematic reviews with
meta-analyses of patients with painful conditions have found that
a strong, non-painful TENS sensation, at or close to the site of
pain, produces optimal analgesic efficacy (Aarskog 2007; Bjordal
2007; Chen 2011; Claydon 2008a; Moran 2011). Central sensiti-
sation contributes to pain associated with fibromyalgia and there-
fore TENS may be beneficial because it has been shown to reduce
this (Ma 2001).
Exercise is recommended as a treatment for fibromyalgia although
adherence to exercise programmes may be poor due to pain and
fatigue (Bidonde 2014; Busch 2008). As TENS has been shown
to reduce pain during movement it may be useful as an adjunct
to assist with participation in exercise and activities of daily liv-
ing. Recently, clinical studies have been published on TENS for
managing symptoms associated with fibromyalgia (Andrade 2014;
Dailey 2013; Lauretti 2013;Mutlu 2013), and there is a published
protocol for a double-blind randomised clinical trial that has yet
to be completed (Noehren 2015). To date, there have been no
systematic reviews on TENS for fibromyalgia. A systematic review
of the current evidence of the effects of TENS for fibromyalgia is
needed so that health professionals, researchers, and patients can
make informed decisions about its use.
The standards used to assess evidence in chronic pain trials have
changed substantially, with particular attention being paid to trial
duration, withdrawals, and statistical imputation following with-
drawal, all of which can substantially alter estimates of efficacy. The
most important change is themove fromusing average pain scores,
or average change in pain scores, to the number of people who
have a large decrease in pain (by at least 50%) and who continue
in treatment, ideally in trials of eight to 12 weeks or longer. Pain
intensity reduction of 50% or more has been shown to correlate
with improvements in comorbid symptoms, function, and quality
of life. These standards are set out in the reference guide for pain
studies (PaPaS 2012). This Cochrane review will assess evidence
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using methods that make both statistical and clinical sense, and
will use developing criteria for what constitutes reliable evidence in
chronic pain (Moore 2010a). The trials included and analysed will
need to meet a minimum of reporting quality (blinding, randomi-
sation), validity (duration, dose and timing, diagnosis, outcomes,
etc), and size (ideally at least 500 participants in a comparison
in which the NNTB is 4 or above; Moore 1998). This approach
sets high standards and marks a departure from how reviews were
conducted previously.
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of TENS for
fibromyalgia in adults. We will assess TENS on its own or added
to usual care in comparisons with placebo (sham) TENS, usual
care, or no treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) or quasi-ran-
domised trials of TENS treatment. We will include single treat-
ment interventions without follow-up but we will give credence to
studies that deliver at least twoweeks of treatment and have a study
duration of at least eight weeks. We will include cross-over and
parallel-group trial designs. We require full journal publication,
with the exception of online clinical trial results summaries of oth-
erwise unpublished clinical trials, and abstracts with sufficient data
for analysis. We will not include short abstracts (usually meeting
reports). We will exclude studies that are non-randomised, studies
of experimental pain, case reports, and clinical observations.
Types of participants
Wewill include studies of adult participants aged 18 years or above
with pain due to fibromyalgia diagnosed using either the 1990
(Wolfe 1990) or 2010 (Wolfe 2010) criteria.
Types of interventions
We will include studies that evaluate TENS administered using
non-invasive techniques for pain relief. We will exclude invasive
techniques such as percutaneous electrical nerve stimulation. We
will include TENS administered using a standard TENS device
(Johnson 2014), regardless of the device manufacturer, which de-
livers biphasic or monophasic pulsed electrical currents that are
greater than 1 mA using at least two surface electrodes. We will
exclude TENS delivered using single probe electrodes (i.e. TENS
pens) and studies investigating ’TENS-like’ devices such as neuro-
muscular electrical stimulation (NMES) devices and interferential
current devices. We will include studies that administer TENS at
intensities that produce perceptible TENS sensations during stim-
ulation. To explore sub-optimal stimulationwewill conduct a sub-
group analysis to compare TENS at intensities described as ’strong’
(optimal) versus those described as ’barely perceptible’, ’faint’, or
’mild’ (sub-optimal). We will include TENS administered on an
area of the body that was sensate at either (a) the site of pain or (b)
over nerve bundles proximal (or near) to the site of pain. We will
include AL-TENS delivered at strong intensities to generate mus-
cle twitches. We will only include TENS delivered at acupuncture
points if the point was lying over nerve bundles proximal (or near)
to the site of pain. We will include any TENS parameters meeting
these criteria; any duration or regularity of TENS treatment; and
either self applied or therapist-applied TENS treatment. We will
include TENS administered as a sole treatment or in combination
with usual care. We will include studies that evaluate TENS ver-
sus:
• placebo TENS (e.g. sham (no current) TENS device);
• no treatment or waiting list control;
• usual care;
• another treatment.
Sham credibility is an issue in TENS studies (Deyo 1990). We
will define a sham TENS device as a device similar to the one used
in the active group but where the current output is modified so
that there is: no electrical current, a barely perceptible electrical
current, or electrical current that ceases within one minute (Rakel
2010; Sluka 2013).We will exclude studies where it is not possible
to isolate the effects of TENS from other treatments.
Types of outcome measures
We anticipate that studies will use a variety of outcome measures,
with the majority of studies using standard subjective scales (nu-
merical rating scale (NRS) or visual analogue scale (VAS)) for pain
intensity or pain relief, or both.Wewill includemeasures of pain at
rest and pain on movement. We are particularly interested in Ini-
tiative on Methods, Measurement, and Pain Assessment in Clin-
ical Trials (IMMPACT) definitions for moderate and substantial
benefit in chronic pain studies (Dworkin 2008). These are defined
as:
• at least 30% pain relief over baseline (moderate);
• at least 50% pain relief over baseline (substantial);
• much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate);
• very much improved on PGIC (substantial).
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These outcomes concentrate on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50%, and ideally with no worse thanmild pain (Moore
2013a; O’Brien 2010). We will include a ’Summary of findings’
table as set out in the author guide (PaPaS 2012). The ’Summary
of findings’ table will include outcomes of at least 30% and at least
50% pain intensity reduction, PGIC, withdrawals due to adverse
events, serious adverse events, and death.We will use the GRADE
approach to assess the quality of evidence related to each of the
key outcomes listed in ’Types of outcome measures’ (Chapter 12,
Higgins 2011), as appropriate. We will extract outcome measure-
ment data before, during, and after the intervention, where data
are available.
Primary outcomes
• Participant-reported pain relief of 30% or greater.
• Participant-reported pain relief of 50% or greater.
• PGIC much or very much improved.
• PGIC very much improved.
Secondary outcomes
• Any pain-related outcome indicating some improvement
(e.g. outcomes from continuous data such as participant-
reported change in pain intensity reported as mean data. Baseline
status may be heterogeneous and large effects in some individuals
may be masked by small effects in others. Therefore, it may only
be possible to make generalised statements).
• Any participant-reported change in health-related quality of
life, including activities of daily living and fatigue, using any
validated tool (e.g. SF-36, SF-6, EuroQol).
• Withdrawals due to lack of efficacy, adverse events, and for
any cause.
• Participants experiencing any adverse event.
• Participants experiencing any serious adverse event. Serious
adverse events typically include any untoward medical
occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, is a congenital anomaly or birth defect, is an
’important medical event’ that may jeopardise the patient, or
may require an intervention to prevent one of the above
characteristics or consequences.
• Specific adverse events, particularly somnolence and
dizziness.
• Any disability-related or mental health-related outcome, if
appropriate.
Search methods for identification of studies
Electronic searches
We will search the following electronic databases using a com-
bination of controlled vocabulary, i.e. medical subject headings
(MeSH) and free-text terms to identify published articles:
• Cochrane Central Register of Controlled Trials
(CENTRAL);
• MEDLINE (OVID) from 1950;
• EMBASE (OVID) from 1980;
• CINAHL (EBSCO) from 1982;
• PsycINFO (OVID) from 1806;
• LILACS from 1982;
• PEDRO from 1929;
• Web of Science (ISI);
• AMED (OVID) from 1985;
• SPORTDiscus (EBSCO) from 1975.
There will be no language restrictions. We will tailor the searches
to the individual databases. We will adapt the MEDLINE search
strategy for the other databases listed. The search strategy will
combine the subject-specific search with phase one and two of the
Cochrane Sensitive Search Strategy for RCTs (as published in sec-
tions 6.4.11.1, 6.3.2.1, and 6.3.3.2 in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011)). The subject-
specific search will use a combination of MeSH (upper case) and
free-text (lower case) terms based on the MEDLINE search strat-
egy via OVID (Appendix 2). We will identify all relevant studies
irrespective of language and translate articles when possible.
Searching other resources
We will review the bibliographies of any RCTs identified and re-
view articles, and we will search clinical trial databases (e.g. Clini-
calTrials.gov (www.clinicaltrials.gov),WorldHealth Organization
(WHO) International Clinical Trials Registry Platform (ICTRP,
http://apps.who.int/trialsearch/), metaRegister of Controlled Tri-
als (mRCT, www.controlled-trials.com/mrct)) to identify addi-
tional published or unpublished data. We will not contact inves-
tigators or study sponsors.
Data collection and analysis
Selection of studies
We will determine eligibility by reading the abstract of each study
identified by the search. We will eliminate studies that clearly do
not satisfy the inclusion criteria, and we will obtain full copies of
the remaining studies. Two review authors will make the decisions.
Two review authors (LSC, GJ) will read these studies indepen-
dently and reach agreement by discussion. Disagreements at any
stage of the process will be resolved by consensus using a third
review author as arbiter (MIJ). We will not anonymise the studies
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in any way before assessment. We will create a PRISMA flow chart
if appropriate (Higgins 2011; Liberati 2009).
Data extraction and management
Two review authors (LSC, GJ) will extract data independently us-
ing a standard form and check for agreement before entry into
RevMan (RevMan 2014). Disagreements will be resolved by con-
sensus using the arbiter (MIJ).We will include information about:
• country of origin;
• study design: cross-over, parallel-group;
• study duration;
• study participants: age, gender, fibromyalgia diagnostic
criteria used, duration of pain and symptoms;
• sample size: active and comparator groups;
• concomitant treatments: pharmacological and non-
pharmacological;
• TENS intervention(s) used: type, electrical parameters,
electrode location, perceptual experience during intervention
including intensity of stimulation, dosing regimen;
• comparison group(s) used: placebo, no treatment, usual
treatment, other treatment, dosing regimen;
• outcomes: time points used including follow-up,
withdrawals;
• adverse and serious adverse effects;
• other: sponsorship, country of origin, conflict of interest
statements.
We will use the data to populate a table of ’Characteristics of
included studies’.
Assessment of risk of bias in included studies
Two review authors (LSC, GJ) will independently assess risk of
bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
with any disagreements resolved by consensus with a third review
author (MIJ) acing as arbiter. We will assess the following for each
study:
• Random sequence generation (checking for possible
selection bias). We will assess the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated). We will exclude studies using a non-
random process (e.g. odd or even date of birth; hospital or clinic
record number).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether the intervention
allocation could have been foreseen in advance of, or during,
recruitment or changed after assignment. We will assess the
methods as: low risk of bias (e.g. telephone or central
randomisation; consecutively numbered, sealed, opaque
envelopes); unclear risk of bias (method not clearly stated); high
risk of bias (studies that do not conceal allocation (e.g. open list).
• Blinding of outcome assessment (checking for possible
detection bias). We will assess the methods used to blind study
participants, care providers, and assessors as follows:
◦ Blinding of participants: low risk of bias (participants
blinded to allocated intervention and unlikely that blinding
broken); unclear risk of bias (insufficient information to permit
judgement of low/high risk of bias); high risk of bias
(participants not blinded to allocated intervention OR
participants blinded to allocated intervention but it is likely that
blinding may have been broken).
◦ Blinding of care provider: low risk of bias (care provider
blinded to allocated intervention and unlikely that blinding
broken); unclear risk of bias (insufficient information to permit
judgement of low/high risk of bias); high risk of bias (care
provider not blinded to allocated intervention and the two
interventions clearly identifiable to the care provider as
experimental and control OR care provider blinded to allocated
intervention but likely that blinding may have been broken).
◦ Blinding of assessor: low risk of bias (outcome assessor
(including ’participants’ with respect to self report outcomes)
blinded to participants’ allocated intervention and unlikely that
blinding broken); unclear risk of bias (insufficient information to
permit judgement of low/high risk of bias); high risk of bias
(outcome assessor (including ’participants’ with respect to self
report outcomes) un-blinded to participants’ allocated
intervention OR outcome assessor blinded to allocated
intervention but likely that blinding may have been broken)).
• Incomplete outcome data (drop-outs). We will check for
possible attrition bias by considering if participant drop-out is
acceptable and described: low risk of bias (< 20% drop-out and
appears to be random with numbers per group provided along
with reasons for drop-out); unclear risk of bias (< 20% and
unclear if random with numbers per group and reasons for drop-
out not described); high risk of bias (> 20% drop-out).
• Incomplete outcome data (protocol violations). We will
consider if participants were analysed as per original group
allocation: low risk of bias (if participants are analysed in the
group to which they were originally assigned); unclear risk of
bias (where insufficient information is provided to determine if
analysis is per protocol or intention-to-treat); high risk of bias
(where per protocol analysis is used, where available data are not
analysed or participants’ data are included in the group to which
they were not originally assigned).
• Selective reporting. We will assess whether studies
selectively report outcomes. We will assess the methods as: low
risk of bias (study protocol is available and all pre-specified
outcomes are reported or study protocol not available but all
expected outcomes are reported); unclear risk of bias (inadequate
information to allow judgement of a study to be classified as ’low
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risk’ or ’high risk’); high risk of bias (incomplete reporting of
specified outcomes. One or more primary outcomes are reported
using measurements or analysis that was not pre-specified. One
or more of the primary outcomes was not pre-specified. One or
more outcomes of interest are reported incompletely and cannot
be entered into meta-analysis. Results for a key outcome
expected to be reported are excluded).
• Size of study (checking for biases confounded by small
size). We will assess this as: low risk of bias (≥ 200 participants
per treatment arm); unclear risk of bias (50 to 199 participants
per treatment arm); high risk of bias (< 50 participants per
treatment arm).
• Other sources of bias. We will consider other factors such
as whether studies were stopped early, differences between groups
at baseline, timing of outcome measurement, co-intervention
comparability, and funding declarations.
Measures of treatment effect
Where available and appropriate we will present quantitative and
intention-to-treat (ITT) data. For dichotomous data (responder
analyses) we will use the Initiative onMethods, Measurement and
Pain Assessment in Clinical Trials (IMMPACT) definitions for in-
terpreting the clinical importance in change in outcome measures
compared to baseline (Dworkin 2008). We will calculate risk ratio
(RR) and risk difference (RD) with 95% confidence intervals (CI)
for dichotomised outcome measures. We will calculate the num-
ber needed to treat to benefit (NNTB) as an absolute measure of
treatment effect where possible. We will present pain outcomes
collected as continuous data on identical scales as mean difference
(MD) with 95% CI. We will present pain outcomes collected as
continuous data using different scales as standardised mean differ-
ence (SMD) with 95% CI. We will interpret reductions in pain
intensity as follows:
• < 15% - no important change;
• ≥ 15% - minimally important change;
• ≥ 30% - moderately important change;
• ≥ 50% - substantially important change
For health-related quality of life data, we will consider a clinical
difference greater than 10% of the scale employed to be minimally
important (Furlan 2009).
The IMMPACT thresholds are based on estimates of the degree
of within-person change from baseline that participants might
consider to be clinically important. The studies in this review are
most likely to present effect sizes as the average between-group
change between intervention groups. There is little consensus or
evidence regarding what the threshold should be for a clinically
important difference in pain intensity based on the between-group
difference during of after the intervention. It has been found that
in pharmacological studies pain outcomes for acute pain (Moore
2011b;Moore 2011c), back pain (Moore 2010d), arthritis (Moore
2010c), and fibromyalgia (Straube 2010), tend to have aU-shaped
rather than a bell-shaped distribution, with some patients expe-
riencing a substantial reduction in symptoms, some minimal to
no improvement, and few experiencing average (moderate) im-
provement. Thus, data expressed as averages may be misleading
as a small average between-group effect size may represent a pro-
portion of participants that actually responded very well to the in-
tervention (Moore 2013c; Moore 2014a). It is unknown whether
outcomes are commonly bi-modally distributed in trials of TENS.
The advantage of focusing on the between-group difference is that
it is the only direct estimate of the average specific effect of the
intervention and a small average between-group effect might ac-
curately represent very small effects of the intervention for most or
all individuals. Wewill use a threshold of 10mmon a 0 to 100mm
VAS for minimally important outcome for pain when analysing
average between-group change, in line with the OMERACT 12
group, which states that the proportion of patients achieving one
or more thresholds of improvement from baseline pain (e.g. >
10%, ≥ 20%, ≥ 30%, ≥ 50%) should be reported in addition to
mean change (Busse 2015). We will interpret these findings with
caution as it remains possible that estimates that fall close to this
point may reflect a treatment that benefits an appreciable number
of patients.
Unit of analysis issues
We will split the control treatment arm between active treatment
arms in a single study if the active treatment arms are not combined
for analysis. In the unlikely event that the unit of randomisation is
not the individual, or where a cross-over design is used, we will not
include the data unless a suitable adjustment for the study design
has been, or can be, made. We will include cross-over designs but
wewill only enter the first period data into themeta-analysis. If this
is not reported we will note this and not include the data. If such
study designs do occur and the data are reported appropriately
then we will include the data using the generic inverse variance
feature.
Dealing with missing data
We will use intention-to-treat (ITT) analysis where the ITT pop-
ulation consists of participants who were randomised, received at
least one dose of the assigned study intervention, and provided at
least one post-baseline assessment. We will assign missing partici-
pants zero improvement wherever possible.
Assessment of heterogeneity
We will deal with clinical heterogeneity by combining studies that
examine similar conditions. We will perform separate analyses
where TENS is compared with different control conditions such
as placebo or no treatment control. We will examine heterogeneity
using visual inspection of forest plots, the I² statistic and L’Abbé
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Plots (L’Abbé 1987), and the Chi2 test. Where significant het-
erogeneity exists we will explore subgroup analyses. Pre-planned
comparisons are described in the section Subgroup analysis and
investigation of heterogeneity.
Assessment of reporting biases
The aim of this review is to use dichotomous outcomes of known
utility and of value to patients (Moore 2010b; Moore 2010c;
Moore 2010d; Moore 2013a). The review will not depend on
what the authors of the original studies chose to report or not,
though clearly difficulties will arise in studies failing to report any
dichotomous results. We will extract and use continuous data,
which will probably poorly reflect efficacy and utility and may be
useful for illustrative purposes only.We will assess publication bias
using amethod designed to detect the amount of unpublished data
with a null effect required to make any result clinically irrelevant
(usually taken to mean a NNTB of 10 or higher; Moore 2008).
We will consider the possible influence of small study samples by
the risk of bias criterion “study size”. When at least 10 studies are
included in a meta-analysis and included studies differ in sample
size wewill visually inspect funnel plots to explore the likelihood of
reporting biases. For studies that have used continuous outcomes
we will use Egger’s test to detect small study bias (Higgins 2011).
We will interpret the results of this process cautiously since we are
aware that all approaches to the quantificationof possible reporting
biases have important limitations (Moore 2008).
Data synthesis
Wewill perform pooling of results where adequate data exist using
Review Manager (RevMan 2014). We will undertake meta-analy-
ses of outcome data only from suitably homogeneous studies using
a random-effects model. Where possible, we will group extracted
data according to outcome and measurement time points. Time
points will include (i) during stimulation or immediately after
stimulation at each treatment session, or both; and (ii) post-inter-
vention follow-up at less than two weeks post-intervention (short-
term), two to sevenweeks post-intervention (mid-term), and eight
weeks or more post-intervention (long-term). For all analyses, we
will explicitly and clearly present the outcome of the ’Risk of bias’
assessments in the reporting. Where inadequate data are found
to support statistical pooling we will complete a narrative synthe-
sis of the evidence using GRADE (Grades of Recommendation,
Assessment, Development and Evaluation, Guyatt 2008) and we
will apply the following criteria to each domain equally for all key
comparisons of the primary outcomes:
• Limitations of studies: downgrade once if > 25% of
participants are from studies at high risk of bias across all risk of
bias criteria;
• Inconsistency: downgrade once if heterogeneity is
statistically significant and I² is ≥ 40%;
• Indirectness: downgrade once if > 50% of participants were
outside the target group;
• Imprecision: downgrade once if there are fewer than 400
participants for continuous data and 300 events for dichotomous
data;
• Publication bias: downgrade once if there is direct evidence
of publication bias.
We will consider single studies to be both inconsistent and impre-
cise (unless the sample size is greater than 400 participants for con-
tinuous data and greater than 300 events for dichotomous data).
We will present pooled effects for all primary outcomes and asso-
ciated GRADE judgements in ’Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
We anticipate too few data for any meaningful subgroup analysis.
If sufficient data are available we plan the following analysis: where
substantial heterogeneity is found (I2 < 40%, P value < 0.1), we
will conduct a subgroup analysis investigating the possible impact
of TENS technique on analgesic efficacy. If appropriate, we will
conduct the following analyses:
• Optimal intensity described as > ’strong’ versus sub-optimal
intensity described as ’barely perceptible’, ’faint’, or ’mild’;
• Low-frequency (≤ 10 Hz) TENS versus other frequency
(e.g. > 10 Hz) TENS;
• Conventional TENS (no visible muscle contraction) versus
AL-TENS (visible phasic muscle contractions);
• Assessment during TENS versus after TENS;
• TENS administered as a sole treatment versus TENS
administered in combination with other treatments;
• TENS administered as a single dose versus repetitive dose;
• Opioid-treated patients versus opioid-naïve patients.
Sensitivity analysis
We anticipate too few data for any meaningful sensitivity analysis.
If sufficient data are available we plan to analyse the effect of
excluding studies with high risk of bias and the effect of using a
random-effects versus a fixed-effect model.
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A P P E N D I C E S
Appendix 1. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with ’any improvement’. Newer trials tend to be larger, avoiding problems
from the random play of chance. Newer trials also tend to be of longer duration, up to 12 weeks, and longer trials provide a more
rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain,
and we are now applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that
may affect our overall assessment. To summarise some of the recent insights that must be considered in this new review:
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore
2011b; Moore 2011c), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases
average results usually describe the experience of almost no-one in the trial. Data expressed as averages are potentially misleading,
unless they can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually
from pain changes or patient global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In
arthritis, trials of less than 12 weeks duration, and especially those shorter than eight weeks, overestimate the effect of treatment
(Moore 2010c); the effect is particularly strong for less effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of patients with at least moderate benefit can be small, even with an effective medicine, falling from 60% with
an effective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013a; Moore 2014b; Straube 2008;
Sultan 2008). A Cochrane review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for
different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia)
(Moore 2009). This indicates that different neuropathic pain conditions should be treated separately from one another, and that
pooling should not be done unless there are good grounds for doing so.
4. Individual patient analyses indicate that patients who get good pain relief (moderate or better) have major benefits in many
other outcomes, affecting quality of life in a significant way (Moore 2010b; Moore 2014b).
5. Imputation methods such as last observation carried forward (LOCF), used when participants withdraw from clinical trials, can
overstate drug efficacy especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012b).
Appendix 2. MEDLINE search strategy via Ovid
1. Exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/
2. TENS.ti
3. TENS.ab
4. TNS.ti
5. TNS.ab
6. ENS.ab
7. ENS.ti
8. Transcutaneous electric$ nerve stimulation OR transcutaneous nerve stimulation.mp
9. Electric$ nerve stimulation OR electrostimulation therap$ OR electro-stimulation therap$.mp
10. Electric$ nerve therap$ OR electroanalgesi$.mp
11. OR/ 1-11
12. Exp Fibromyalgia/
13. Fibromyalgi$. tw
14. Fibrositis.tw
15. OR 12-14
16. 11 AND 15
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